Amundi Acquires 11,548 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Amundi boosted its holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 129,933 shares of the medical instruments supplier’s stock after purchasing an additional 11,548 shares during the quarter. Amundi owned about 0.22% of Merit Medical Systems worth $12,752,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Atria Investments Inc grew its stake in Merit Medical Systems by 25.5% in the third quarter. Atria Investments Inc now owns 10,461 shares of the medical instruments supplier’s stock valued at $1,034,000 after acquiring an additional 2,127 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Merit Medical Systems in the third quarter valued at approximately $580,000. Impax Asset Management Group plc acquired a new stake in Merit Medical Systems in the third quarter valued at approximately $11,860,000. Natixis Advisors LLC grew its stake in Merit Medical Systems by 1.5% in the third quarter. Natixis Advisors LLC now owns 67,544 shares of the medical instruments supplier’s stock valued at $6,675,000 after acquiring an additional 1,009 shares during the period. Finally, Quest Partners LLC grew its stake in Merit Medical Systems by 92.6% in the third quarter. Quest Partners LLC now owns 11,843 shares of the medical instruments supplier’s stock valued at $1,170,000 after acquiring an additional 5,695 shares during the period. 99.66% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Merit Medical Systems news, insider Brian G. Lloyd sold 25,000 shares of the business’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $99.50, for a total value of $2,487,500.00. Following the sale, the insider now directly owns 38,993 shares in the company, valued at $3,879,803.50. The trade was a 39.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Fred P. Lampropoulos sold 31,320 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $103.86, for a total value of $3,252,895.20. Following the sale, the chief executive officer now owns 1,086,028 shares in the company, valued at approximately $112,794,868.08. The trade was a 2.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,132 shares of company stock valued at $11,139,521. Insiders own 3.70% of the company’s stock.

Analysts Set New Price Targets

MMSI has been the subject of a number of research reports. Barrington Research reduced their price objective on Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Raymond James lifted their target price on Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday, December 31st. Wells Fargo & Company cut their target price on Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $116.00 target price (up previously from $114.00) on shares of Merit Medical Systems in a research report on Wednesday, January 29th. Finally, Needham & Company LLC cut their target price on Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $110.78.

Merit Medical Systems Stock Up 1.3 %

MMSI stock opened at $98.94 on Friday. The stock’s fifty day simple moving average is $103.52 and its two-hundred day simple moving average is $100.57. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. Merit Medical Systems, Inc. has a 1-year low of $70.70 and a 1-year high of $111.45. The stock has a market cap of $5.82 billion, a P/E ratio of 48.50, a P/E/G ratio of 2.34 and a beta of 0.91.

Merit Medical Systems Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.